Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Schiff

Showing results (71-80 of 83) with videos related to

Pageof 9
Sort By:
Arthritis Research & Therapy|September 11, 2015
Certolizumab pegol plus methotrexate 5-year results from the rheumatoid arthritis prevention of structural damage (RAPID) 2 randomized controlled trial and long-term extension in rheumatoid arthritis patientsJosef S Smolen, Ronald van Vollenhoven, Arthur Kavanaugh, et al.
Arthritis and Rheumatism|July 19, 2002
Effects of prasterone on corticosteroid requirements of women with systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trialMichelle A Petri, Robert G Lahita, Ronald F Van Vollenhoven, et al.
Rheumatology and Therapy|December 8, 2021
Differential Changes in ACPA Fine Specificity and Gene Expression in a Randomized Trial of Abatacept and Adalimumab in Rheumatoid ArthritisOmar Jabado, Michael A Maldonado, Michael Schiff, et al.
Arthritis and Rheumatism|April 9, 2005
Evaluation of the efficacy of etoricoxib in ankylosing spondylitis: results of a fifty-two-week, randomized, controlled studyDésirée van der Heijde, Herbert S B Baraf, Cesar Ramos-Remus, et al.
Annals of the Rheumatic Diseases|September 15, 2011
Clinical response and tolerability to abatacept in patients with rheumatoid arthritis previously treated with infliximab or abatacept: open-label extension of the ATTEST StudyMichael Schiff, Mauro Keiserman, Christine Codding, et al.
The New England Journal of Medicine|September 16, 2005
Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibitionMark C Genovese, Jean-Claude Becker, Michael Schiff, et al.
Arthritis and Rheumatism|March 2, 2006
Infliximab treatment maintains employability in patients with early rheumatoid arthritisJosef S Smolen, Chenglong Han, Désirée van der Heijde, et al.
Arthritis and Rheumatism|November 6, 2004
Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trialE William St Clair, Désirée M F M van der Heijde, Josef S Smolen, et al.
Arthritis and Rheumatism|March 2, 2006
Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trialJosef S Smolen, Désirée M F M Van Der Heijde, E William St Clair, et al.
Arthritis Research & Therapy|September 20, 2017
Patient-reported outcomes of baricitinib in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatmentMichael Schiff, Tsutomu Takeuchi, Roy Fleischmann, et al.
Pageof 9

Showing results (71-80 of 83) with videos related to

Sort By:
Pageof 9
Arthritis Research & Therapy|September 11, 2015
Certolizumab pegol plus methotrexate 5-year results from the rheumatoid arthritis prevention of structural damage (RAPID) 2 randomized controlled trial and long-term extension in rheumatoid arthritis patientsJosef S Smolen, Ronald van Vollenhoven, Arthur Kavanaugh, et al.
Arthritis and Rheumatism|July 19, 2002
Effects of prasterone on corticosteroid requirements of women with systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trialMichelle A Petri, Robert G Lahita, Ronald F Van Vollenhoven, et al.
Rheumatology and Therapy|December 8, 2021
Differential Changes in ACPA Fine Specificity and Gene Expression in a Randomized Trial of Abatacept and Adalimumab in Rheumatoid ArthritisOmar Jabado, Michael A Maldonado, Michael Schiff, et al.
Arthritis and Rheumatism|April 9, 2005
Evaluation of the efficacy of etoricoxib in ankylosing spondylitis: results of a fifty-two-week, randomized, controlled studyDésirée van der Heijde, Herbert S B Baraf, Cesar Ramos-Remus, et al.
Annals of the Rheumatic Diseases|September 15, 2011
Clinical response and tolerability to abatacept in patients with rheumatoid arthritis previously treated with infliximab or abatacept: open-label extension of the ATTEST StudyMichael Schiff, Mauro Keiserman, Christine Codding, et al.
The New England Journal of Medicine|September 16, 2005
Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibitionMark C Genovese, Jean-Claude Becker, Michael Schiff, et al.
Arthritis and Rheumatism|March 2, 2006
Infliximab treatment maintains employability in patients with early rheumatoid arthritisJosef S Smolen, Chenglong Han, Désirée van der Heijde, et al.
Arthritis and Rheumatism|November 6, 2004
Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trialE William St Clair, Désirée M F M van der Heijde, Josef S Smolen, et al.
Arthritis and Rheumatism|March 2, 2006
Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trialJosef S Smolen, Désirée M F M Van Der Heijde, E William St Clair, et al.
Arthritis Research & Therapy|September 20, 2017
Patient-reported outcomes of baricitinib in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatmentMichael Schiff, Tsutomu Takeuchi, Roy Fleischmann, et al.
Pageof 9